Wang Metabolic Syndrome

Underlying Mechanisms and Drug Therapies
1. Auflage 2011
ISBN: 978-0-470-92271-2
Verlag: John Wiley & Sons
Format: EPUB
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 508 Seiten, E-Book

This book provides a comprehensive overview of the development of metabolic syndrome, the underlying mechanisms and therapeutic strategies for drug development. The authors examine the context of underlying molecular pathways and integrated physiology, then expanding the discussion to diseases associated with metabolic syndrome. The development of drug therapies for these diseases and complications is extensively covered. The book offers a comprehensive and in-depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism-based drug discovery and clinical implications.

Autoren/Hrsg.

Wang, Minghan

Inhaltsverzeichnis

Introduction (Minghan Wang).
Contributors.
Part I. The physiology of metabolic tissues under normal anddisease states.
Chapter 1: Gut as an endocrine organ: the role ofnutrient-sensing in energy metabolism (Minghan Wang).
Chapter 2: Central glucose sensing and control of food intakeand energy homeostasis (Lourdes Mounien and BernardThorens).
Chapter 3: Abnormalities in insulin secretion in type 2 diabetesmellitus (Taly Meas and Pierre-Jean Guillausseau).
Chapter 4: Adipokine production by adipose tissue: A noveltarget for treating metabolic syndrome and its sequelae (VanessaDeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and PeterZahradka).
Chapter 5: Hepatic metabolic dysfunctions in type 2 diabetes:Insulin resistance and impaired glucose production and lipidsynthesis (Ruojing Yang).
Chapter 6: Energy metabolism in skeletal muscle and its link toinsulin resistance (Minghan Wang).
Part II. Metabolic diseases and current therapies.
Chapter 7: Mechanisms and complications of metabolic syndrome(Minghan Wang).
Chapter 8: Emerging therapeutic approaches for dyslipidemiaassociated with high LDL and low HDL (Margrit Schwarz and Jae B.Kim).
Chapter 9: Mechanism of action of niacin: implications foratherosclerosis and drug discovery (Devan Marar, Shobha H.Ganji, Vaijinath S. Kamanna, and Moti L. Kashyap).
Chapter 10: Current anti-diabetic therapies and mechanisms(Minghan Wang).
Part III. Drug targets for anti-diabetic therapies.
Chapter 11: GLP-1 biology, signaling mechanisms, physiology, andclinical studies (Remy Burcelin, Cendrine Cabou1, ChristopheMagnan, and Pierre Gourdy).
Chapter 12: Dipeptidyl peptidase IV inhibitors for treatment ofdiabetes (McIntosh, CHS, Kim, S-J., Pederson, RA, Heiser, U, andDemuth, H-U).
Chapter 13: Sodium glucose co-transporter 2 inhibitors(Margaret Ryan and Serge A. Jabbour).
Chapter 14: Fibroblast growth factor 21 as a novel metabolicregulator (Radmila Micanovic, James D. Dunbar, and AlexeiKharitonenkov).
Chapter 15: Sirtuins as potential drug targets for metabolicdiseases (Qiang Tong).
Chapter 16: 11?-hydroxysteroid dehydrogenase type 1 as atherapeutic target for type 2 diabetes (Clarence Hale and DavidJ. St. Jean, Jr.).
Chapter 17: Monoclonal antibodies for the treatment of type 2diabetes: A case study with glucagon receptor blockade (Hai Yan,Wei Gu, and Murielle Veniant-Ellison).
Part IV. Lessons learned and future outlook.
Chapter 18: Drug development for metabolic diseases: past,present and future (Minghan Wang).
Index.